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Immunization of Adolescents
Recommendations of
the Advisory Committee on Immunization Practices,
the American Academy of Pediatrics,
the American Academy of Family Physicians, and
the American Medical Association
Summary
This report concerning the immunization of adolescents (i.e., persons
11–21 years of age, as defined by the American Medical Association [AMA] and
the American Academy of Pediatrics [AAP]) is a supplement to previous publica-
tions (i.e., MMWR 1994;43 [No. RR-1]1-38; the AAP 1994 Red Book: Report of the
Committee on Infectious Diseases; Summary of Policy Recommendations for
Periodic Health Examination, August 1996 from  the American Academy of Fam-
ily Physicians [AAFP]; and AMA Guidelines for Adolescent Preventive Services
[GAPS]: Recommendations and Rationale). This report presents a new strategy
to improve the delivery of vaccination services to adolescents and to integrate
recommendations for vaccination with other preventive services provided
to adolescents. This new strategy emphasizes vaccination of adolescents
11–12 years of age by establishing a routine visit to their health-care providers.
Specifically, the purposes of this visit are to a) vaccinate adolescents who have
not been previously vaccinated with varicella virus vaccine, hepatitis B vaccine,
or the second dose of the measles, mumps, and rubella (MMR) vaccine; b) pro-
vide a booster dose of tetanus and diphtheria toxoids; c) administer other
vaccines that may be recommended for certain adolescents; and d) provide
other recommended preventive services. The recommendations for vaccination
of adolescents are based on new or current information for each vaccine. The
most recent recommendations from ACIP, AAP, AAFP, and AMA concerning spe-
cific vaccines and delivery of preventive services should be consulted for details
(Exhibit 2).
BACKGROUND
In the United States, vaccination programs that focus on infants and children have
decreased the occurrence of many childhood, vaccine-preventable diseases (1 ). How-
ever, many adolescents (i.e., persons 11–21 years of age i.e., as defined by the
American Medical Association [AMA] and the American Academy of Pediatrics [AAP])
and young adults (i.e., persons 22–39 years of age) continue to be adversely affected
by vaccine-preventable diseases (e.g., varicella, hepatitis B, measles, and rubella), par-
tially because vaccination programs have not focused on improving vaccination
coverage among adolescents.
These recommendations for the immunization of adolescents were developed to
improve vaccination coverage among adolescents and focus on establishing a routine
visit to health-care providers (i.e., providers) for adolescents ages 11–12 years. Such a
Vol. 45 / No. RR-13 MMWR 1
visit provides the opportunity for a) ensuring vaccination of those adolescents not
previously vaccinated with hepatitis B vaccine, varicella virus vaccine (if indicated), or
the second dose of the measles, mumps, and rubella (MMR) vaccine; b) administering
a tetanus and diphtheria toxoid (Td) booster; c) administering other vaccines that may
be recommended for certain adolescents; and d) providing other recommended pre-
ventive services.
Flexibility in scheduling vaccinations is an important factor for improving
vaccination coverage among adolescents. Because multiple-dose vaccines or simulta-
neous administration of several vaccines may be indicated for adolescents (Table 1),
providers may need to be flexible in determining which vaccines to administer during
the initial visit and which to administer on return visits.
IMMUNIZATION AS A PREVENTIVE HEALTH SERVICE FOR
ADOLESCENTS
Administration of vaccinations should be integrated with other preventive services
provided to adolescents. The importance of improving the vaccination levels and of
providing other preventive services indicated for adolescents and young adults has
been emphasized recently by many national organizations (Exhibit 1). In particular,
AAP has advocated and provided specific recommendations for the vaccination of
adolescents (2,3 ). Similarly, AMA and the Health Resources and Services Administra-
tion (HRSA) have proposed comprehensive recommendations that provide a
framework for organizing the content and delivery of preventive health services (in-
cluding vaccinations) for adolescents (4,5 ). The United States Preventive Services
Task Force (USPSTF) has advocated specific vaccinations for adolescents that are
based on the patient’s age and risk factors (6 ). In addition, the American Academy of
Family Physicians (AAFP) has recommended delivery of preventive services based on
reviews by USPSTF and the AAFP Commission on Clinical Policies and Research (7 ).
Guidelines recommended by these organizations include the delivery of preventive
health services during a series of regular visits by adolescents to providers. These
services include specific guidance on health behaviors; screening for biomedical, be-
havioral, and emotional conditions; and delivery of other health services, including
vaccinations. The recommendations for vaccination of adolescents adopted by the
Advisory Committee on Immunization Practices (ACIP), AAP, AAFP, and AMA are con-
sistent with those of other groups that promote preventive health services for
adolescents.
RATIONALE FOR VACCINE ADMINISTRATION DURING AN
ADOLESCENT’S VISIT TO PROVIDERS
Hepatitis B Vaccine
In the United States, most persons infected with hepatitis B virus (HBV) acquired
their infection as young adults or adolescents. HBV is transmitted primarily through
sexual contact, injecting-drug use, regular household contact with a chronically in-
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TABLE 1. Recommended childhood immunization schedule*—United States,
July–December 1996
 * This schedule is updated and published periodically. Vaccines are listed under the routinely recommended ages.
† Infants born to hepatitis B surface antigen (HBsAg)-negative mothers should receive the first dose
(Hep B-1) of 2.5 µg of Recombivax HB® (Merck & Co.) or 10 µg of Engerix-B® (SmithKline Beecham). The
second dose (Hep B-2) should be administered 1 month after the first dose. Infants born to HBsAg-positive
mothers should receive 0.5 mL hepatitis B immune globulin (HBIG) within 12 hours of birth, and either
5 µg of Recombivax HB® or 10 µg of Engerix-B® at a separate site. The second dose is recommended at
age 1–2 months and the third dose at age 6 months. Infants born to mothers whose HBsAg status is
unknown should receive either 5 µg of Recombivax HB® or 10 µg of Engerix-B® within 12 hours of birth.
The second dose of vaccine is recommended at age 1 month and the third dose (Hep B-3) at age 6 months.
§Adolescents who have not received three doses of hepatitis B vaccine should initiate or complete the
series at ages 11–12 years. The second dose should be administered at least 1 month after the first dose,
and the third dose should be administered at least 4 months after the first dose and at least 2 months
after the second dose.
¶ The fourth dose of diphtheria and tetanus toxoids and pertussis vaccine (DTP) may be administered at
age 12 months if at least 6 months have elapsed since the third dose of DTP. Diphtheria and tetanus
toxoids and acellular pertussis vaccine (DTaP) is licensed for the fourth and/or fifth vaccine dose(s) for
children ages ≥15 months and may be preferred for these doses in this age group. Tetanus and diphtheria
toxoids, adsorbed, for adult use (Td) is recommended at ages 11–12 years if at least 5 years have elapsed
since the last dose of DTP, DTaP, or diphtheria and tetanus toxoids, adsorbed, for pediatric use (DT).
** Three H. influenzae type b (Hib) conjugate vaccines are licensed for infant use. If PedvaxHIB® (Merck
& Co.) Haemophilus b conjugate vaccine (Meningococcal Protein Conjugate) (PRP-OMP) is administered
at ages 2 and 4 months, a dose at 6 months is not required. After completing the primary series, any
Hib conjugate vaccine may be used as a booster.
††Oral poliovirus vaccine (OPV) is recommended for routine vaccination of infants. Inactivated poliovirus
vaccine (IPV) is recommended for persons—or household contacts of persons—with a congenital or
acquired immune-deficiency disease or an altered immune status resulting from disease or
immunosuppressive therapy and is an acceptable alternative for other persons. The primary three-dose
series for IPV should be given with a minimum interval of 4 weeks between the first and second doses
and 6 months between the second and third doses.
§§The second dose of measles, mumps, and rubella vaccine (MMR) is routinely recommended at ages
4–6 years or at ages 11–12 years but may be administered at any visit provided at least 1 month has
elapsed since receipt of the first dose.
¶¶ Varicella virus vaccine (Var) can be administered to susceptible children and adolescents at any time after
age 12 months. Unvaccinated adolescents who lack a reliable history of chickenpox should be vaccinated
at ages 11–12 years.
Use of trade names and commercial sources is for identification only and does not imply endorsement by
the Public Health Service or the U.S. Department of Health and Human Services.
Source: Advisory Committee on Immunization Practices, American Academy of Pediatrics, and American
Academy of Family Physicians.
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fected person, or occupational exposure. However, the source of infection is unknown
for approximately one third of persons who have acute hepatitis B (8 ).
A comprehensive vaccination strategy to eliminate transmission of HBV through
routine vaccination of infants, adolescents ages 11–12 years, and adolescents who are
at increased risk for HBV infection has been adopted (3,7,9,10 ). Any reduction in HBV-
related liver disease resulting from universal vaccination of infants cannot be
expected until vaccinated children reach adolescence and adulthood.
Routine vaccination of adolescents 11–12 years of age who have not been vacci-
nated previously is an effective strategy for more rapidly lowering the incidence of
HBV infection and assisting in the elimination of HBV transmission in the United
States (3,10 ). An adolescent’s visit at ages 11–12 years gives the provider an opportu-
nity to initiate protection against HBV before the adolescent begins high-risk
behaviors. Unvaccinated adolescents >12 years of age who are at increased risk for
HBV infection also should be vaccinated (10 ). Such adolescents are at increased risk
for HBV infection and should be vaccinated against hepatitis B if they a) have multiple
sexual partners (i.e., more than one partner in a 6-month period), b) use illegal inject-
ing drugs, c) are males who have sex with males, d) have sexual or regular household
contact with a person who is positive for hepatitis B surface antigen, e) are health-care
or public-safety workers who are occupationally exposed to human blood, f) are un-
dergoing hemodialysis, g) are residents of institutions for the developmentally
disabled, h) are administered clotting factors, or i) travel to an area of high or interme-
diate HBV endemicity for ≥6 months. In addition, AAP recommends that providers
administer hepatitis B vaccine to all adolescents for whom they provide services (3 ).
Adolescents can be vaccinated against hepatitis B in various settings, including
schools and providers’ offices. In the United States, school-based demonstration pro-
jects to vaccinate adolescents against hepatitis B have achieved >70% vaccination
coverage (11–13 ).
Adolescents should receive three age-appropriate doses of hepatitis B vaccine
(Table 2). Hepatitis B vaccine is highly immunogenic in adolescents and young adults
when administered in varying three-dose schedules (14,15 ). A schedule of 0, 1–2, and
4–6 months is recommended. Flexibility in scheduling is an important factor for
achieving high rates of vaccination in adolescents. When the vaccination schedule is
interrupted, the vaccine series does not require reinitiation (CDC, unpublished data;
16 ) . Studies of “off-schedule” vaccinations indicate that if the series is interrupted
after the first dose, the second dose should be administered as soon as possible, and
the second and third doses should be separated by an interval of at least 2 months. If
only the third dose is delayed, it should be administered as soon as possible. Intervals
of up to 1 year between administration of the first and third doses induce excellent
antibody responses (15 ), and studies are in progress to evaluate longer intervals.
Measles, Mumps, and Rubella Vaccine
The sustained decline of measles in the United States has been associated with a
shift in occurrence from children to infants and young adults. During 1990–1994, 47%
of reported cases occurred in persons ages ≥10 years, compared with only 10% during
1960–1964 (CDC, unpublished data; 17 ). During the 1980s, outbreaks of measles
occurred among school-age children in schools with measles-vaccination levels
















TABLE 2. Recommended schedule of vaccinations for adolescents ages 11–12 years
Immunobiologic Indications Name Dose Frequency Route
Hepatitis A vaccine Adolsecents who are at
increased risk of hepatitis A





A total of two doses at
 0,¶ 6–12 mos
A total of two doses at
 0, 6–18 mos
IM**
IM
Hepatitis B vaccine Adolescents not vaccinated





A total of three doses
 at 0, 1–2, 4–6 mos
A total of three doses
 at 0, 1–2, 4–6 mos
IM
IM
Influenza vaccine Adolescents who are at
increased risk for complications
caused by influenza or who have
contact with persons at increased
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reliable history of chickenpox
VARIVAX®* 0.5 mL One dose¶¶ SC
 *Manufacturer’s product name.
† Enzyme-linked immunosorbent assay (ELISA) unit.
§ Alternative dosage and schedule of 360 EL.U./0.5 mL and a total of three doses administered at 0, 1, and 6–12 months.




¶¶ Adolescents ≥13 years of age should be administered a total of two doses (0.5 mL/dose) subcutaneously at 0 and 4–8 weeks.
of ≥98% (18 ). Primary vaccine failure was considered the principal contributing factor
in these outbreaks. As a result, beginning in 1989, a two-dose measles-vaccination
schedule for students in primary schools, secondary schools, and colleges and univer-
sities was recommended (18–20 ). This two-dose vaccination schedule provides
protection to ≥98% of persons vaccinated. Administration of a second dose of MMR at
entry to elementary school (i.e., at ages 4–6 years) or junior high or middle school (i.e.,
at ages 11–12 years) is recommended(21–23 ). State policies for implementing the
two-dose strategy have varied; some states require the second dose for entry into
primary school, and others require it for entry into middle school. Because the recom-
mendation for a second dose of MMR was made in 1989, many children born before
1985 (and some children born after 1985, depending on local policy) may not have
received the second vaccine dose. The routine visit to providers at ages 11–12 years
affords an opportunity to administer a second dose of MMR to adolescents who have
not received two doses of MMR at ≥12 months of age. 
MMR should not be given to adolescents who are known to be pregnant or to ado-
lescents who are considering becoming pregnant within 3 months of vaccination.
Asking adolescents if they are pregnant, excluding those who say they are, and ex-
plaining the theoretical risk of fetal infection to the other female adolescents are
recommended precautions.
Tetanus and Diphtheria Toxoids
Although booster doses of Td are recommended at 10-year intervals, no special
strategies have been developed to ensure that this recommendation is fully imple-
mented. During 1991–1994, 191 (95%) of the 201 reported cases of tetanus in the
United States occurred in persons ages ≥20 years, and nine (45%) of the 20 reported
cases of diphtheria occurred in persons ages ≥20 years (CDC, unpublished data). Data
from a serosurvey conducted in Minnesota indicated that 62% of persons 18–39 years
of age lacked adequate protection against diphtheria (24 ).
Epidemic diphtheria has reemerged in the New Independent States (NIS) of the
former Soviet Union and has resulted in >47,000 cases reported in 1994 and >50,000
in 1995 (CDC, unpublished data; 25 ). Although no imported cases were reported in the
United States during those years, ≥20 cases of diphtheria were reported in Europe,
and two cases occurred among U.S. citizens who resided or were traveling in the NIS.
This threat of infection underscores the importance of maintaining high levels of diph-
theria immunity in the U.S. population.
Recent data from CDC’s National Health and Nutrition Examination Survey
(NHANES III) suggested that immunity to tetanus varied with age (26 ). Among chil-
dren ages 6–16 years, 82% had protective levels of tetanus antitoxin (defined as a
serum level >0.15 IU per mL). Immunity in persons decreased at ages 9–13 years, with
15%–36% of these persons unprotected (CDC, unpublished data). Immunity also var-
ied inversely with the length of time since the last tetanus vaccination. Among
children who were reported as being vaccinated 6–10 years before the serologic sur-
vey, 28% lacked immunity to tetanus, compared with 14% who were reported as being
vaccinated 1–5 years before the survey and 5% who were reported as being vacci-
nated ≤1 year before the survey (27 ). A Td booster is essential to ensure long-lasting
immunity against tetanus. Lowering the age for administration of the first Td booster
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from ages 14–16 years to ages 11–12 years should increase compliance and thereby
reduce the susceptibility of adolescents to tetanus and diphtheria.
Administering the Td booster at ages 11–12 years provides a rationale for a routine
visit to providers for adolescents, regardless of their need for other vaccines. Data
suggest there should be no increased risk for serious side effects to Td when the first
booster dose is administered at ages 11–12 years rather than at ages 14–16 years
(CDC, unpublished data).
With the exception of the Td booster at ages 11–12 years, routine boosters should
be administered every 10 years. If a dose of Td has been administered after receipt of
tetanus- and diphtheria-containing vaccine at ages 4–6 years and before the routine
Td booster at ages 11–12 years, the dose at ages 11–12 years is not indicated. The next
dose should follow the last dose by 10 years, unless specifically indicated because of
a tetanus-prone injury (i.e., persons who sustain a tetanus-prone injury should be
administered a Td booster immediately if >5 years have elapsed since their last
Td booster).
Varicella Virus Vaccine
Before varicella virus vaccine became available in 1995, most persons in the United
States contracted varicella (i.e., chickenpox), resulting in an estimated 4 million infec-
tions annually. At present, approximately 20% of adolescents ages 11–12 years
remain susceptible to varicella (CDC, unpublished data). The rate of complications,
including death, is greater for persons who contract chickenpox when they are
≥15 years of age.
Varicella virus vaccine should be administered to adolescents ages 11–12 years if
they have not been vaccinated and do not have a reliable history of chickenpox (7,
27,28 ). At ages 11–12 years, providers should assess the adolescent’s need for
varicella virus vaccine and administer the vaccine to those who are eligible. When
administered to children <13 years of age, a single dose of vaccine induces protective
antibodies in >95% of recipients. For susceptible persons ≥13 years of age, two doses
separated by 4–8 weeks are recommended.
Varicella vaccine should not be given to adolescents who are known to be pregnant
or to adolescents who are considering becoming pregnant within 1 month of vaccina-
tion. Asking adolescents if they are pregnant, excluding those who say they are, and
explaining the potential effects of the vaccine virus on the fetus to the other female
adolescents are recommended precautions.
OTHER VACCINES INDICATED FOR CERTAIN ADOLESCENTS
Influenza Vaccine
More than 8 million children and adolescents in the United States, including
2.2 million persons ages 10–18 years who have asthma (CDC, unpublished data), have
at least one medical condition that places them at high risk for complications associ-
ated with influenza. Such adolescents should be vaccinated annually for influenza;
however, few actually receive the vaccine.
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Adolescents at high risk who should be administered influenza vaccine annually
are those who a) have chronic disorders of the pulmonary system (including those
who have asthma) or the cardiovascular system; b) reside in chronic-care facilities that
house persons of any age who have chronic medical conditions; c) have required
regular medical follow-up or hospitalization during the preceding year because of
chronic metabolic disease(s) (including those who have diabetes mellitus), renal dys-
function, hemoglobinopathy, or immunosuppression (including those who have
immunosuppression caused by medication); or d) receive long-term aspirin therapy
and, therefore, may be at risk for contracting Reye syndrome after influenza. In addi-
tion, adolescents who have close contact* with persons who meet any of these
conditions or with persons ≥65 years of age should be administered influenza vaccine
annually. Students in institutional settings (e.g., those residing in dormitories) should
be encouraged to receive influenza vaccine annually to minimize any disruption of
routine activities during epidemics. In addition, any adolescent may be vaccinated an-
nually to reduce the likelihood of acquiring influenza infection.
Administration of influenza vaccine to adolescents ages 11–12 years may assist in
establishing the lifetime practice of annual influenza vaccination in persons for whom
it is indicated. Providers should administer influenza vaccine to adolescents who visit
them for routine care if vaccination is indicated and if their visit is during the time of
year appropriate for influenza vaccination (i.e., September–December); such adoles-
cents should be scheduled for an additional visit if they are seen at a time of year when
vaccination is not indicated. Adolescents may receive influenza vaccine at the same
time they receive other recommended vaccines. Additional strategies are needed to
improve delivery of influenza vaccine to adolescents for whom it is indicated.
Pneumococcal Polysaccharide Vaccine
Approximately 340,000 persons 2–18 years of age have chronic illnesses associ-
ated with increased risk for pneumococcal disease or its complications and should
receive the 23-valent pneumococcal vaccine. Adolescents who should be vaccinated
include those who have a) anatomic or functional asplenia (including sickle cell dis-
ease), b) nephrotic syndrome, c) cerebrospinal-fluid leaks, or d) conditions associated
with immunosuppression (including human immunodeficiency virus [HIV]).
Revaccination is recommended for adolescents at highest risk for serious pneumo-
coccal infection and those likely to experience rapid decline in pneumococcal-
antibody levels, provided ≥5 years have passed since administration of the first dose
of pneumococcal vaccine. The possible need for subsequent doses following revacci-
nation requires further study. Persons at highest risk and persons likely to have a rapid
decline in pneumococcal-antibody levels include those who have a) splenic dysfunc-
tion or anatomic asplenia, b) sickle cell disease, c) HIV infection, d) Hodgkin’s disease,
e) lymphoma, f) multiple myeloma, g) chronic renal failure, h) nephrotic syndrome, or
i) other conditions associated with immunosuppression (e.g., undergoing organ trans-
plantation or receiving immunosuppressive chemotherapy).
*Close contact occurs when persons live with, work with, or otherwise are frequently in close
physical proximity to other persons.
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Hepatitis A Vaccine
Each year, approximately 140,000 persons in the United States are infected with
hepatitis A virus (HAV). The highest rates of disease occur among persons 5–14 years
of age. Most cases of hepatitis A can be attributed to person-to-person transmission.
Adolescents who plan to travel to or work in a country that has high or intermediate
endemicity of hepatitis A virus (HAV) infection* should be administered hepatitis A
vaccine or immune globulin (29 ). For adolescents who plan to travel repeatedly to or
reside for long periods in such areas, administration of hepatitis A vaccine rather than
immune globulin is preferred (29 ).
Unvaccinated adolescents who reside in a community that has a high rate of
HAV infection and periodic outbreaks of hepatitis A disease also should be vaccinated.
During outbreaks in such a community, age-specific disease rates provide an indirect
indication of the age groups in which a large percentage of the group has prior immu-
nity and, therefore, would benefit little from vaccination. Often the upper-age cutoff
for hepatitis A vaccination is between 10 years of age and 15 years of age. In addition,
adolescents should be vaccinated against hepatitis A if they a) have chronic liver dis-
ease, b) are administered clotting factors, c) use illegal injecting or noninjecting drugs
(i.e., if local epidemiologic data indicate current or past outbreaks have occurred
among persons who have such risk behaviors), or d) are males who have sex with
males.
SCHEDULING VACCINATIONS
Simultaneous Administration of Vaccines
Extensive clinical experience and experimental evidence from studies of infants
and children have strengthened the scientific basis for administering certain vaccines
simultaneously. Although specific studies have not been conducted regarding the
simultaneous administration of all vaccines recommended for routine use in adoles-
cents, no evidence has established that this practice is unsafe or ineffective (30 ).
All indicated vaccinations should be administered at the scheduled immunization
visit for adolescents who are 11–12 years of age. However, some adolescents may
require multiple (i.e., four or more) vaccinations, and the provider may choose not to
administer all indicated vaccines during the same visit. In these circumstances, the
provider may prioritize which vaccines to administer during the visit and schedule the
adolescent for one or more return visits. Factors to consider in this decision include
which vaccines require multiple doses, which diseases pose an immediate threat to
the adolescent, and whether the adolescent is likely to return for scheduled visits.
Documentation of Previous Vaccinations
Providers may encounter adolescents who do not have documentation of pre-
viously received vaccines. In these circumstances, providers should attempt to assess
each adolescent’s vaccination status through documentation obtained from the par-
ent, previous providers, or school records. If documentation of an adolescent’s
*This includes countries other than Australia, Canada, Japan, New Zealand and those located
in western Europe.
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vaccination status is not available at the time of the visit, the following strategy is
recommended while awaiting documentation: a) for those vaccinations required by
law or regulation that the adolescent previously was subject to, assume that the
adolescent has been vaccinated (unless required vaccinations have not been adminis-
tered for religious, philosophic, or medical reasons) and withhold those vaccinations;
and b) administer those vaccines that the adolescent previously was not subject to by
law or regulation.
STATE VACCINATION LAWS AND REGULATIONS
In the United States, state vaccination laws and regulations for kindergarten
through grade 12 are effective in ensuring high coverage levels among school atten-
dees and have led to a marked decline of overall morbidity and mortality from
vaccine-preventable diseases. Additional state laws and regulations requiring docu-
mentation of up-to-date immunization of adolescents or a reliable history of disease-
related immunity at entry into sixth or seventh grade would ensure implementation of
these recommendations and would lead to further reduction in transmission of
vaccine-preventable disease.
RECOMMENDATIONS FOR VACCINATION OF ADOLESCENTS
The recommendations for administering each vaccine are consistent with current
ACIP, AAP, AAFP, and AMA documents (Exhibit 2). However, the Td recommendation
has been changed recently such that the ages at which the first Td booster is adminis-
tered may be lowered from 14–16 years to 11–12 years (21–23 ). General
recommendations and vaccine-specific recommendations for providers are as fol-
lows:
General Recommendations
• Establish a visit to providers for adolescents ages 11–12 years to screen for im-
munization deficiencies, and administer those indicated vaccines that have not
been received (Table 1). During the initial visit, schedule appointments to receive
needed doses of vaccine that are not administered during the initial visit. Provide
other indicated preventive services during this and all other visits.
• Check the vaccination status of adolescents during each subsequent visit to
providers and correct any deficiencies, including those associated with the three-
dose series of hepatitis B vaccinations.
Vaccine-Specific Recommendations
• Hepatitis B vaccine. Vaccinate adolescents 11–12 years of age who have not been
vaccinated previously with the three-dose series of hepatitis B vaccine. Ensure
completion of the series by scheduling the vaccinations that are needed and by
following up on those adolescents who do not receive these scheduled vaccina-
tions. In addition, adolescents >12 years of age who are at increased risk for
HBV infection should be vaccinated.
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• MMR (second dose). Administer the second dose of MMR to adolescents who
have not received two doses of MMR at ≥12 months of age.
• Td booster. Administer a booster dose of Td vaccine to adolescents at ages 11–
12 or 14–16 years if they have received the primary series of vaccinations and if
no dose has been received during the previous 5 years. All subsequent, routine
Td boosters (i.e., in the absence of tetanus-prone injury) should be administered
at 10-year intervals.
• Varicella virus vaccine. Administer varicella virus vaccine to adolescents ages 11–
12 years who do not have a reliable history of chickenpox and who have not been
vaccinated with varicella virus vaccine.
• Influenza vaccine. Administer influenza vaccine annually to adolescents who, be-
cause of an underlying medical condition, are at high risk for complications
associated with influenza. If seen at a time of year when vaccination is not indi-
cated, schedule the adolescent for an influenza vaccination at the appropriate
vaccination time (i.e., September–December). Vaccinate adolescents who have
close contact with persons at high risk for complications associated with influ-
enza. This vaccine also may be administered to adolescents who have no
underlying medical condition to reduce their risk for influenza infection.
• Pneumococcal polysaccharide vaccine. Administer pneumococcal vaccine to
adolescents who have chronic illnesses associated with increased risk for pneu-
mococcal disease or its complications. Use adolescents’ visits to providers to
ensure that the vaccine has been administered to persons for whom it is indi-
cated. 
• Hepatitis A vaccine. Administer hepatitis A vaccine to unvaccinated adolescents
who a) plan to travel to or work in a country that has high or intermediate en-
demicity of HAV infection*; b) reside in a community that has a high rate of HAV
infection and periodic outbreaks of hepatitis A disease; c) are administered clot-
ting factors; or d) have any of the following conditions or risk behaviors: chronic
liver disease, use of illegal injecting or noninjecting drugs (i.e., if local
epidemiologic data indicate current or past outbreaks of hepatitis A disease have
occurred among persons who have such risk behaviors), or if they are males who
have sex with males.
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